Pharmacogenomics: Historical perspective and current status

Methods in Molecular Biology

Volumn 1015, Issue , 2013, Pages 3-22

  Charlab, Rosane ^a   Zhang, Lei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse event; Drug metabolizing enzyme; Drug transporter; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; Polymorphism; Targeted therapy

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CETUXIMAB; CLOPIDOGREL; CRIZOTINIB; ERLOTINIB; FLUCLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IRINOTECAN; LAPATINIB; LUMIRACOXIB; PANITUMUMAB; SIMVASTATIN; TAMOXIFEN; TETRABENAZINE; TRASTUZUMAB; VEMURAFENIB; WARFARIN; XIMELAGATRAN;

ALTERNATIVE RNA SPLICING; BIOINFORMATICS; BREAST CANCER; BREAST METASTASIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; DEPRESSION; DNA METHYLATION; DNA SEQUENCE; DNA TEMPLATE; DOSE RESPONSE; DRESS SYNDROME; DRUG DISPOSITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; ERYTHROLEUKEMIA; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GLUCURONIDATION; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUNTINGTON CHOREA; HYDROXYLATION; INTERNATIONAL NORMALIZED RATIO; LIVER INJURY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MELANOMA; METASTATIC COLORECTAL CANCER; MOLECULAR CLONING; MULTICENTER STUDY (TOPIC); MYOPATHY; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INJURY; STAPHYLOCOCCUS INFECTION; STEADY STATE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC VARIATION; GENOME, HUMAN; GENOTYPING TECHNIQUES; HAPMAP PROJECT; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS;

EID: 84880380617     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-435-7_1     Document Type: Review

References (102)

1. Offi t K (2011) Personalized medicine: New genomics, old lessons. Hum Genet 130(1): 3-14
2. Weinshilboum R, Wang L (2004) Pharmacogenomics: Bench to bedside. Nat Rev Drug Discov 3(9):739-748
3. Kalow W et al (1998) Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8(4):283-289
4. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348(6):538-549
5. Roden DM et al (2006) Pharmacogenomics: Challenges and opportunities. Ann Intern Med 145(10):749-757
6. Camilleri M, Saito YA (2008) Pharmacogenomics in gastrointestinal disorders. Methods Mol Biol 448:395-412
7. Kirk RJ et al (2008) Implications of pharmacogenomics for drug development. Exp Biol Med (Maywood) 233(12):1484-1497
8. McLeod HL, Evans WE (2001) Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101-121
9. Watters JW, McLeod HL (2003) Cancer pharmacogenomics: Current and future applications. Biochim Biophys Acta 1603(2): 99-111
10. Hudson KL (2011) Genomics, health care, and society. N Engl J Med 365(11): 1033-1041
11. Snyder LH (1932) Studies in human inheritance. IX. The inheritance of taste defi ciency in man. Ohio J Sci 32:436-468
12. Kim UK et al (2003) Positional cloning of the human quantitative trait locus underlying taste sensitivity to phenylthiocarbamide. Science 299(5610):1221-1225
13. Motulsky AG (1957) Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 165(7):835-837
14. Vogel F (1959) Moderne probleme der humangenetik. Ergebn Inn Med Kinderheilkd 12:52-125
15. Nebert DW et al (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metab Rev 40(2):187-224
16. Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63(2):437-459
17. Gonzalez FJ et al (1988) Characterization of the common genetic defect in humans defi -cient in debrisoquine metabolism. Nature 331(6155):442-446
18. Blum M et al (1990) Human arylamine N-acetyltransferase genes - isolation, chromosomal localization, and functional expression. DNA Cell Biol 9(3):193-203
19. Krynetski EY et al (1995) A single-point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92(4):949-953
20. Vesell ES (1989) Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 41(3):535-552
21. Shin J et al (2009) Pharmacogenetics: From discovery to patient care. Am J Health Syst Pharm 66(7):625-637
22. Roden DM et al (2011) Pharmacogenomics: The genetics of variable drug responses. Circulation 123(15):1661-1670
23. Evans WE, Relling MV (1999) Relling, Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286(5439):487-491
24. Belle DJ, Singh H (2008) Genetic factors in drug metabolism. Am Fam Physician 77(11): 1553-1560
25. Gaedigk A et al (2008) The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234-242
26. Desta Z et al (2002) Clinical signifi cance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913-958
27. Mini E, Nobili S (2009) Pharmacogenetics: Implementing personalized medicine. Clin Cases Miner Bone Metab 6(1):17-24
28. Venter JC et al (2001) The sequence of the human genome. Science 291(5507): 1304-1351
29. Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860-921
30. den Dunnen JT, Antonarakis SE (2001) Nomenclature for the description of human sequence variations. Hum Genet 109(1): 121-124
31. Kacevska M et al (2011) Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 89(6): 902-907
32. O'Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: Ethnic differences in sus-ceptibility to the effects of chemotherapy. Clin Cancer Res 15(15):4806-4814
33. Lee W et al (2005) Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist 10(2):104-111
34. Judson R et al (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1(1):15-26
35. Fujiwara Y, Minami H (2010) An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 11(3):391-406
36. Becquemont L (2009) Pharmacogenomics of adverse drug reactions: Practical applications and perspectives. Pharmacogenomics 10(6): 961-969
37. Wu X et al (2009) Strategies to identify pharmacogenomic biomarkers: Candidate gene, pathway-based, and genome-wide approaches. In: Innocenti F (ed) Genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, Totowa NJ, pp 353-370
38. Feero WG et al (2010) Genomic medicine - an updated primer. N Engl J Med 362(21): 2001-2011
39. Metzker ML (2010) Sequencing technologies - the next generation. Nat Rev Genet 11(1):31-46
40. Wilke RA et al (2007) Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat Rev Drug Discov 6(11):904-916
41. Andrade RJ et al (2009) Drug-induced liver injury: Insights from genetic studies. Pharmacogenomics 10(9):1467-1487
42. Huang YS (2010) Tailored drug therapy for mitigating drug-induced liver injury: Is this the era of genetic screening? Pers Med 7(1):5-8
43. Wang L et al (2011) Genomics and drug response. N Engl J Med 364(12):1144-1153
44. Daly AK et al (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fl ucloxacillin. Nat Genet 41(7):816-819
45. Kindmark A et al (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8(3):186-195
46. Singer JB et al (2010) A genome-wide study identifi es HLA alleles associated with lumiracoxib- related liver injury. Nat Genet 42(8):711-714
47. Tujios S, Fontana RJ (2011) Mechanisms of drug-induced liver injury: From bedside to bench. Nat Rev Gastroenterol Hepatol 8(4): 202-211
48. Pirmohamed M (2010) Pharmacogenetics of idiosyncratic adverse drug reactions. Handb Exp Pharmacol 196:477-491
49. Becquemont L (2010) HLA: A pharmacogenomics success story. Pharmacogenomics 11(3):277-281
50. Mallal S et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358(6):568-579
51. Hung SI et al (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16(4):297-306
52. TEGRETOL(Carbamazepine) Labeling [Online]. http://www.accessdata.fda.gov/ d r u g s a t f d a - d o c s / l a b e l / 2 0 1 1 /016608s100s102 s.s., 018927s041s042,020 234s031s033lbl.pdf . Accessed 31 Oct 2011
53. McCormack M et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364(12):1134-1143
54. Ozeki T et al (2011) Genome-wide association study identifi es HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20(5):1034-1041
55. Somkrua R et al (2011) Association of HLAB* 5801 allele and Allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: A systematic review and metaanalysis. BMC Med Genet 12(1):118
56. Niemi M (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87(1):130-133
57. Link E et al (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 359(8):789-799
58. Walko CM, McLeod H (2009) Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol 6(3):153-162
59. Innocenti F, Ratain MJ (2006) Pharmacogenetics of irinotecan: Clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8):1211-1221
60. Wilke RA, Dolan ME (2011) Genetics and variable drug response. JAMA 306(3):306-307
61. Carlquist JF, Anderson JL (2011) Pharmacogenetic mechanisms underlying unanticipated drug responses. Discov Med 11(60):469-478
62. Lovly CM, Carbone DP (2011) Lung cancer in 2010: One size does not fi t all. Nat Rev Clin Oncol 8(2):68-70
63. Biankin AV, Hudson TJ (2011) Somatic variation and cancer: Therapies lost in the mix. Hum Genet 130(1):79-91
64. Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516
65. Shaw AT et al (2011) Effect of crizotinib on overall survival in patients with advanced nonsmall-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12(11):1004-1012
66. Hutchinson L (2010) Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib. Nat Rev Clin Oncol 7(8):424
67. Ellis LM, Hicklin DJ (2009) Resistance to targeted therapies: Refi ning anticancer therapy in the era of molecular oncology. Clin Cancer Res 15(24):7471-7478
68. PLAVIX (Clopidogrel) Labeling [Online]. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/020839s051lbl.pdf .Accessed 28 Aug
69. Mega JL et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354-362
70. Mega JL et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A metaanalysis. JAMA 304(16):1821-1830
71. Scott SA et al (2011) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and Clopidogrel therapy. Clin Pharmacol Ther 90(2):328-332
72. Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13(5):247-252
73. Kim MJ et al (2009) A regulatory science perspective on warfarin therapy: A pharmacogenetic opportunity. J Clin Pharmacol 49(2): 138-146
74. Scordo MG et al (2002) Infl uence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702-710
75. Sconce EA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106(7):2329-2333
76. Marsh S et al (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4(2):473-474
77. Yuan HY et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14(13):1745-1751
78. Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: Regulatory, scientifi c, and clinical issues. J Thromb Thrombolysis 25(1):45-51
79. Caraco Y et al (2008) CYP2C9 genotypeguided warfarin prescribing enhances the effi -cacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 83(3):460-470
80. Gage BF et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3): 326-331
81. Lenzini P et al (2010) Integration of genetic, clinical, and INR data to refi ne warfarin dosing. Clin Pharmacol Ther 87(5): 572-578
82. COUMADIN (Warfarin) prescribing information. [Online]. www.accessdata.fda.gov/drugsatfda-docs/label/2010/009218s108lbl.pdf .Accessed 28 Aug
83. Tetrabenazine Clinical Pharmacology Review. [Online]. http://www.accessdata.fda.gov/d r u g s a t f d a - d o c s / n d a / 2 0 0 8 /021894s000TOC.cfm . Accessed 28 Aug
84. XENAZINE (Tetrabenazine) Labeling [Online]. http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/021894s004lbl. pdf . Accessed 28 Aug
85. Stingl Kirchheiner JC, Brockmoller J (2011) Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther 89(2):198-209
86. Zineh I, Pacanowski MA (2011) Pharmacogenomics in the assessment of therapeutic risks versus benefi ts: Inside the United states food and drug administration. Pharmacotherapy 31(8):729-735
87. Diamandis M et al (2010) Personalized medicine: Marking a new epoch in cancer patient management. Mol Cancer Res 8(9): 1175-1187
88. Houle D et al (2010) Phenomics: The next challenge. Nat Rev Genet 11(12):855-866
89. Pirmohamed M et al (2011) The phenotype standardization project: Improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 89(6): 784-785
90. Lanktree MB et al (2010) Phenomics: Expanding the role of clinical evaluation in genomic studies. J Investig Med 58(5): 700-706
91. Tracy RP (2008) 'Deep phenotyping': Characterizing populations in the era of genomics and systems biology. Curr Opin Lipidol 19(2):151-157
92. Carson PE et al (1956) Enzymatic defi ciency in primaquine-sensitive erythrocytes. Science 124(3220):484-485
93. Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet 271: 576-577
94. Harris HW et al (1958) Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am Rev Tuberc 78(6):944-948
95. Evans DA et al (1960) Genetic control of isoniazid metabolism in man. Br Med J 2(5197):485-491
96. Mahgoub A et al (1977) Polymorphic hydroxylation of Debrisoquine in man. Lancet 2(8038):584-586
97. Eichelbaum M et al (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16(3):183-187
98. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651-662
99. Ge D et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401
100. Eichler HG et al (2011) Bridging the effi cacyeffectiveness gap: A regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495-506
101. Bertilsson L et al (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111-122
102. Janne PA et al (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8(9): 709-723